IL310246A - Novel spiropyrrolidine derived antiviral agents - Google Patents
Novel spiropyrrolidine derived antiviral agentsInfo
- Publication number
- IL310246A IL310246A IL310246A IL31024624A IL310246A IL 310246 A IL310246 A IL 310246A IL 310246 A IL310246 A IL 310246A IL 31024624 A IL31024624 A IL 31024624A IL 310246 A IL310246 A IL 310246A
- Authority
- IL
- Israel
- Prior art keywords
- page
- compound
- nmr
- acetone
- mhz
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163227206P | 2021-07-29 | 2021-07-29 | |
| US17/479,248 US11325916B1 (en) | 2021-07-29 | 2021-09-20 | Spiropyrrolidine derived antiviral agents |
| US202263324367P | 2022-03-28 | 2022-03-28 | |
| PCT/US2022/024772 WO2023009187A1 (en) | 2021-07-29 | 2022-04-14 | Novel spiropyrrolidine derived antiviral agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL310246A true IL310246A (en) | 2024-03-01 |
Family
ID=85087186
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL310246A IL310246A (en) | 2021-07-29 | 2022-04-14 | Novel spiropyrrolidine derived antiviral agents |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP4376834A4 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2024529476A (cg-RX-API-DMAC10.html) |
| KR (1) | KR20240044452A (cg-RX-API-DMAC10.html) |
| AU (1) | AU2022319598A1 (cg-RX-API-DMAC10.html) |
| CA (1) | CA3173702A1 (cg-RX-API-DMAC10.html) |
| IL (1) | IL310246A (cg-RX-API-DMAC10.html) |
| MX (1) | MX2024001377A (cg-RX-API-DMAC10.html) |
| WO (1) | WO2023009187A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7559223B2 (ja) | 2020-08-24 | 2024-10-01 | ギリアード サイエンシーズ， インコーポレイテッド | リン脂質化合物及びその使用 |
| TWI925033B (zh) | 2020-10-16 | 2026-05-11 | 美商基利科學股份有限公司 | 磷脂化合物及其用途 |
| WO2023283256A1 (en) | 2021-07-09 | 2023-01-12 | Aligos Therapeutics, Inc. | Anti-viral compounds |
| AU2023303408A1 (en) | 2022-07-06 | 2024-12-19 | Aligos Therapeutics, Inc. | Anti-viral compounds |
| EP4612156A1 (en) * | 2022-11-02 | 2025-09-10 | Aligos Therapeutics, Inc. | Anti-viral compounds |
| CN119139307B (zh) * | 2023-12-29 | 2025-09-23 | 上海柯君医药科技有限公司 | 螺环类化合物在制备3CLpro蛋白酶抑制剂或药物中的用途 |
| WO2025221657A1 (en) * | 2024-04-15 | 2025-10-23 | Aligos Therapeutics, Inc. | Anti-viral compounds |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006061714A2 (en) * | 2004-12-09 | 2006-06-15 | Pfizer Inc. | Anticoronaviral compounds and compositions, their pharmaceutical uses and materials for their synthesis |
| US8222288B2 (en) * | 2006-08-30 | 2012-07-17 | The Regents Of The University Of Michigan | Small molecule inhibitors of MDM2 and the uses thereof |
| CA2661354C (en) * | 2006-08-30 | 2012-12-18 | The Regents Of The University Of Michigan | New small molecule inhibitors of mdm2 and the uses thereof |
| US8575208B2 (en) * | 2007-02-27 | 2013-11-05 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases |
| UY37381A (es) * | 2016-08-30 | 2018-03-23 | Glaxosmithkline Ip No 2 Ltd | Compuestos que inhiben proteasas 3c y 3cl y métodos de uso de los mismos |
| US12398147B2 (en) * | 2021-05-11 | 2025-08-26 | Enanta Pharmaceuticals, Inc. | Macrocyclic spiropyrrolidine derived antiviral agents |
| US11325916B1 (en) * | 2021-07-29 | 2022-05-10 | Enanta Pharmaceuticals, Inc. | Spiropyrrolidine derived antiviral agents |
| WO2023086400A1 (en) * | 2021-11-12 | 2023-05-19 | Enanta Pharmaceuticals, Inc. | Novel spiropyrrolidine derived antiviral agents |
| WO2023125825A1 (en) * | 2021-12-29 | 2023-07-06 | Shanghai Curegene Pharmaceutical Co., Ltd. | Anticoronviral compounds and compositions and uses thereof |
-
2022
- 2022-04-14 IL IL310246A patent/IL310246A/en unknown
- 2022-04-14 JP JP2024505183A patent/JP2024529476A/ja active Pending
- 2022-04-14 CA CA3173702A patent/CA3173702A1/en active Pending
- 2022-04-14 MX MX2024001377A patent/MX2024001377A/es unknown
- 2022-04-14 KR KR1020247006429A patent/KR20240044452A/ko active Pending
- 2022-04-14 AU AU2022319598A patent/AU2022319598A1/en active Pending
- 2022-04-14 EP EP22850031.0A patent/EP4376834A4/en active Pending
- 2022-04-14 WO PCT/US2022/024772 patent/WO2023009187A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| KR20240044452A (ko) | 2024-04-04 |
| EP4376834A4 (en) | 2025-06-18 |
| WO2023009187A1 (en) | 2023-02-02 |
| AU2022319598A1 (en) | 2024-02-08 |
| EP4376834A1 (en) | 2024-06-05 |
| CA3173702A1 (en) | 2023-01-29 |
| JP2024529476A (ja) | 2024-08-06 |
| MX2024001377A (es) | 2024-03-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12479854B2 (en) | Spiropyrrolidine derived antiviral agents | |
| US11976084B2 (en) | Spiropyrrolidine derived antiviral agents | |
| US11325916B1 (en) | Spiropyrrolidine derived antiviral agents | |
| US11858945B2 (en) | Alkyne-containing antiviral agents | |
| WO2022109363A1 (en) | Novel spiropyrrolidine derived antiviral agents | |
| AU2021313130A1 (en) | Functionalized peptides as antiviral agents | |
| WO2023107419A1 (en) | Saturated spirocyclics as antiviral agents | |
| US11919910B2 (en) | Spiropyrrolidine derived antiviral agents | |
| WO2023196307A1 (en) | Novel spiropyrrolidine derived antiviral agents | |
| WO2023091561A1 (en) | Novel spiropyrrolidine derived antiviral agents | |
| WO2023086352A1 (en) | Novel spiropyrrolidine derived antiviral agents | |
| AU2022319598A1 (en) | Novel spiropyrrolidine derived antiviral agents | |
| WO2022036018A1 (en) | Functionalized peptides as antiviral agents | |
| US20230103494A1 (en) | Novel spiropyrrolidine derived antiviral agents | |
| US12145941B2 (en) | Heterocyclic antiviral agents | |
| WO2023003610A1 (en) | Novel spiropyrrolidine derived antiviral agents | |
| HK40071048A (en) | Novel spiropyrrolidine derived antiviral agents | |
| EA050743B1 (ru) | Новые противовирусные агенты на основе производных спиропирролидина | |
| CN118043045A (zh) | 新型螺吡咯烷衍生的抗病毒药物 |